Marie Pierre J, Fromigué Olivia
Laboratory of Osteoblast Biology and Pathology Unité 606 INSERM, Hopital Lariboisière, 2 rue Ambroise Paré, 75475 Paris Cedex 10, France.
Regen Med. 2006 Jul;1(4):539-48. doi: 10.2217/17460751.1.4.539.
Bone marrow-derived mesenchymal stem cells (MSCs) are adherent cells that differentiate into chondroblasts, osteoblasts and adipocytes. In this short review, we summarize the molecular mechanisms that are known to control osteoblast differentiation and osteogenic potential of MSCs in vitro. We discuss the advances made in gene-based therapy to promote osteogenic differentiation of MSCs and the perspectives for an optimal use of MSCs for bone tissue regeneration or repair. One important challenge at the present time is to identify factors and pathways that promote osteogenic commitment of MSCs in order to use MSCs with functional potential for optimal bone repair in humans. In this context, genomic and proteomic analyses may help to identify molecules that could be used to promote osteogenic differentiation of human MSCs. In the future this may lead to selective therapeutic strategies for tissue engineering application in bone regeneration and repair in humans.
骨髓间充质干细胞（MSCs）是一种贴壁细胞，可分化为成软骨细胞、成骨细胞和脂肪细胞。在这篇简短的综述中，我们总结了已知的在体外控制MSCs成骨细胞分化和成骨潜能的分子机制。我们讨论了基于基因的疗法在促进MSCs成骨分化方面取得的进展，以及将MSCs最佳用于骨组织再生或修复的前景。目前一个重要的挑战是确定促进MSCs成骨定向分化的因素和途径，以便在人类中使用具有功能潜力的MSCs实现最佳的骨修复。在这种情况下，基因组和蛋白质组分析可能有助于识别可用于促进人类MSCs成骨分化的分子。未来，这可能会导致在人类骨再生和修复的组织工程应用中采用选择性治疗策略。
